<DOC>
	<DOCNO>NCT01640717</DOCNO>
	<brief_summary>The primary objective ass safety efficacy data Escherichia coli-derived cPMP patient molybdenum cofactor deficiency ( MoCD ) .</brief_summary>
	<brief_title>A Retrospective , Observational , Noninterventional Data Collection Study Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate ( cPMP )</brief_title>
	<detailed_description />
	<mesh_term>Metal Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>1 . Male female age . 2 . Patient MoCD type A , suspect type A , type B . 3 . Patient previously receive cPMP intravenous route administration . 4 . Parent ( ) legal guardian ( ) , depend local regulation , voluntarily provide write informed consent Investigator , Investigator 's designee , Sponsor designee review , collect , transmit , analyze data extract medical record . In case decease patient parent legal guardian could locate , appropriate ethical review committee may assign another person legal representative provide consent , applicable per local country regulation . Patient 's parent ( ) legal guardian ( ) unable understand nature scope study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>